Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT)

Charytan, D. M. et al. (2015) Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT). American Journal of Kidney Diseases, 66(3), pp. 429-440. (doi:10.1053/j.ajkd.2015.02.324) (PMID:25935581)

Full text not currently available from Enlighten.

Abstract

Background The cause of death in patients with chronic kidney disease (CKD) varies with CKD severity, but variation has not been quantified. Study Design Retrospective analysis of prospective randomized clinical trial. Setting and Participants We analyzed 4,038 individuals with anemia and diabetic CKD from TREAT, a randomized trial comparing darbepoetin alfa and placebo. Predictors Baseline estimated glomerular filtration rate (eGFR) and protein-creatinine ratio (PCR). Outcomes Cause of death as adjudicated by a blinded committee.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Charytan, D. M., Lewis, E. F., Desai, A. S., Weinrauch, L. A., Ivanovich, P., Toto, R. D., Claggett, B., Liu, J., Hartley, L. H., Finn, P., Singh, A. K., Levey, A. S., Pfeffer, M. A., McMurray, J. J.V., and Solomon, S. D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:American Journal of Kidney Diseases
Publisher:W.B. Saunders Co.
ISSN:0272-6386
ISSN (Online):1523-6838

University Staff: Request a correction | Enlighten Editors: Update this record